Picture [iito] Back into Ad 650x80px
Document › Details

ERS Genomics Ltd.. (12/13/18). "Press Release: ERS Genomics and Lonza Enter into CRISPR/Cas9 Technology Licensing Deal". Dublin.

Organisations Organisation ERS Genomics Ltd.
  Organisation 2 Lonza Pharma & Biotech (division)
  Today Lonza Pharma Biotech & Nutrition (LPBN) (segment)
  Group Lonza Group (Group)
Products Product CRISPR gene editing technology
  Product 2 contract manufacturing (biologicals)
Index terms Index term Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech
  Index term 2 ERS Genomics–MacDougall Biomedical Communications: public relations, 201606 service existent by MacDougall
Persons Person Rhodes, Eric (ERS Genomics 201606– CEO before Horizon Discovery since 201201 before Sigma-Aldrich + Sangamo Biosciences)
  Person 2 Brkulj, Mario (MacDougall 201511 VP before MorphoSys + Biocom)

ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. Lonza will have the ability to utilize CRISPR/Cas9 in its bioproduction products and services and also for use in induced pluripotent stem cells (iPSC) for research applications.

“Lonza is the world’s leading contract manufacturing organization of biologics and we are thrilled that they have chosen to use CRISPR/Cas9 to enhance their capabilities,” commented Eric Rhodes, CEO of ERS Genomics. “We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way.”

Financial details of the agreement were not disclosed.

ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; livestock; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit

Contact ERS Genomics:

MacDougall Biomedical Communications
Mario Brkulj or Kara Mazey
Direct: +49 89 2420 9345 or +1 781 235 3060

Record changed: 2019-04-14


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for ERS Genomics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] No Content Marketing 650x80px

» top